Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.
作者信息
Ryder S D
机构信息
Queens Medical Centre, Nottingham NG7 2UH, UK.
出版信息
Gut. 2003 May;52 Suppl 3(Suppl 3):iii1-8. doi: 10.1136/gut.52.suppl_3.iii1.
Abstract
摘要
相似文献
1
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.
Gut. 2003 May;52 Suppl 3(Suppl 3):iii1-8. doi: 10.1136/gut.52.suppl_3.iii1.
2
Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.
Minerva Gastroenterol Dietol. 2009 Jun;55(2):123-38.
3
Current approach to hepatocellular carcinoma.
Surg Clin North Am. 2010 Aug;90(4):803-16. doi: 10.1016/j.suc.2010.04.010. Epub 2010 Jun 8.
4
Hepatocellular cancer.
West Indian Med J. 2009 Jun;58(3):273-6.
5
[Scrutiny and management of a patient with hepatocarcinoma].
Rev Gastroenterol Mex. 2005 Nov;70 Suppl 3:69-70.
6
Optimal management of hepatocellular carcinoma: challenges and opportunities.
J Gastroenterol Hepatol. 2010 Aug;25(8):1336-8. doi: 10.1111/j.1440-1746.2010.06373.x.
7
Management of hepatocellular carcinoma in the age of liver transplantation.
Int J Surg. 2009 Aug;7(4):324-9. doi: 10.1016/j.ijsu.2008.12.041. Epub 2009 Jan 6.
8
Hepatocellular carcinoma in a case of Wilson's disease treated with radiofrequency ablation therapy.
Intern Med. 2011;50(13):1433-7. doi: 10.2169/internalmedicine.50.5203. Epub 2011 Jul 1.
9
Hepatocellular carcinoma: status in the era of liver transplantation.
J Okla State Med Assoc. 2009 Dec;102(12):355-61.
10
Hepatocellular carcinoma: current management.
Curr Probl Surg. 2010 Jan;47(1):10-67. doi: 10.1067/j.cpsurg.2009.09.003.
引用本文的文献
1
Prevalence and risk factors of portal vein thrombosis following hepatectomy: a systematic review and meta‑analysis.
Wideochir Inne Tech Maloinwazyjne. 2025 Jan 15;20(1):36-43. doi: 10.20452/wiitm.2025.17929. eCollection 2025 Apr 9.
2
FCGR2A contributes to M2 macrophages polarization in HCC through IL-4/JAK/STAT6 axis.
Transl Oncol. 2025 Aug;58:102429. doi: 10.1016/j.tranon.2025.102429. Epub 2025 Jun 6.
3
Isolated calvarial lesion as the initial presentation of metastatic hepatocellular carcinoma: A case report and review of the literature.
Surg Neurol Int. 2025 Jan 10;16:6. doi: 10.25259/SNI_507_2024. eCollection 2025.
4
Differentiating Well-Differentiated from Poorly-Differentiated HCC: The Potential and the Limitation of Gd-EOB-DTPA in the Presence of Liver Cirrhosis.
Diagnostics (Basel). 2024 Aug 2;14(15):1676. doi: 10.3390/diagnostics14151676.
5
Current and Emerging Molecular Markers of Liver Diseases: A Pathogenic Perspective.
Gene Expr. 2022;21(1):9-19. doi: 10.14218/gejlr.2022.00010. Epub 2022 Sep 28.
6
CASCADE: Context-Aware Data-Driven AI for Streamlined Multidisciplinary Tumor Board Recommendations in Oncology.
Cancers (Basel). 2024 May 23;16(11):1975. doi: 10.3390/cancers16111975.
7
Ultrasensitive dynamic light scattering immunodetection of alpha-fetoprotein using heptamer-amplified nanoparticle crosslinking aggregation.
Mikrochim Acta. 2024 Jun 13;191(7):387. doi: 10.1007/s00604-024-06437-7.
8
The Synergy of Gene Targeting Drug Icaritin Soft Capsule with Immunomodulator and TACE Brings New Hope for Drug Combination in Patients with Advanced Liver Cancer: A Case Report and Literature Review.
Cancer Manag Res. 2023 Jul 18;15:707-717. doi: 10.2147/CMAR.S414487. eCollection 2023.
9
Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma.
Cancers (Basel). 2023 Jun 26;15(13):3347. doi: 10.3390/cancers15133347.
10
A convoluted path to the diagnosis of hepatocellular carcinoma in a resource-limited setting.
SAGE Open Med Case Rep. 2023 Apr 25;11:2050313X231168292. doi: 10.1177/2050313X231168292. eCollection 2023.
本文引用的文献
1
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Hepatology. 2002 Sep;36(3):687-91. doi: 10.1053/jhep.2002.35071.
2
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
Lancet. 2002 May 18;359(9319):1734-9. doi: 10.1016/S0140-6736(02)08649-X.
3
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.
Hepatology. 2002 May;35(5):1164-71. doi: 10.1053/jhep.2002.33156.
4
Short-term results of radiofrequency ablation in liver tumors.
Am J Surg. 2000 Jun;179(6):527. doi: 10.1016/s0002-9610(00)00254-3.
5
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
Lancet. 2000 Sep 2;356(9232):802-7. doi: 10.1016/S0140-6736(00)02654-4.
6
Percutaneous microwave coagulation therapy for superficial hepatocellular carcinoma on the liver surface.
Am J Gastroenterol. 2000 Sep;95(9):2401-3. doi: 10.1111/j.1572-0241.2000.02355.x.
7
Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.
Ann Surg. 2000 Sep;232(3):381-91. doi: 10.1097/00000658-200009000-00010.
8
Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.
J Epidemiol. 2000 Jul;10(4):234-40. doi: 10.2188/jea.10.234.
9
10
Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival.
Hepatology. 2000 Aug;32(2):233-8. doi: 10.1053/jhep.2000.9603.
Zotero 插件